| Style | Citing Format | 
|---|---|
| MLA | Nurzadeh M, et al.. "The Sequestosome 1 Protein: Therapeutic Vulnerabilities in Ovarian Cancer." Clinical and Translational Oncology, vol. 25, no. 10, 2023, pp. 2783-2792. | 
| APA | Nurzadeh M, Ghalandarpoorattar SM, Ghalandarpoorattar SN, Rabiei M (2023). The Sequestosome 1 Protein: Therapeutic Vulnerabilities in Ovarian Cancer. Clinical and Translational Oncology, 25(10), 2783-2792. | 
| Chicago | Nurzadeh M, Ghalandarpoorattar SM, Ghalandarpoorattar SN, Rabiei M. "The Sequestosome 1 Protein: Therapeutic Vulnerabilities in Ovarian Cancer." Clinical and Translational Oncology 25, no. 10 (2023): 2783-2792. | 
| Harvard | Nurzadeh M et al. (2023) 'The Sequestosome 1 Protein: Therapeutic Vulnerabilities in Ovarian Cancer', Clinical and Translational Oncology, 25(10), pp. 2783-2792. | 
| Vancouver | Nurzadeh M, Ghalandarpoorattar SM, Ghalandarpoorattar SN, Rabiei M. The Sequestosome 1 Protein: Therapeutic Vulnerabilities in Ovarian Cancer. Clinical and Translational Oncology. 2023;25(10):2783-2792. | 
| BibTex | @article{ author = {Nurzadeh M and Ghalandarpoorattar SM and Ghalandarpoorattar SN and Rabiei M}, title = {The Sequestosome 1 Protein: Therapeutic Vulnerabilities in Ovarian Cancer}, journal = {Clinical and Translational Oncology}, volume = {25}, number = {10}, pages = {2783-2792}, year = {2023} } | 
| RIS | TY  - JOUR AU - Nurzadeh M AU - Ghalandarpoorattar SM AU - Ghalandarpoorattar SN AU - Rabiei M TI - The Sequestosome 1 Protein: Therapeutic Vulnerabilities in Ovarian Cancer JO - Clinical and Translational Oncology VL - 25 IS - 10 SP - 2783 EP - 2792 PY - 2023 ER - |